RxDoctor Payments Data

Julian Bell, MD

Pulmonary Disease · Medford, ORNPI 1497840813

Payments from drug & device makers

$637in general payments, 2019–2025

Across 19 payments — averaging $33.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$282
  • Inspire Medical Systems, Inc.$116
  • GSK$57
  • AstraZeneca$40
  • Boehringer Ingelheim$36
  • Mylan Specialty L.p.$30
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$637 in reported general payments places this provider in the 55th percentile of 154 pulmonary disease providers in Oregon.

See all pulmonary disease providers in Oregon

Medicare billing

Part B allowed, 2024
$62,842
Medicare patients
445
Services billed
1,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate21$275,859
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$97,864
Pirfenidone18$24,541
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,488
Spiriva RespimatTiotropium Bromide11$5,522
Atrovent HfaIpratropium Bromide11$4,993
Breo ElliptaFluticasone/Vilanterol11$4,390
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,843
Albuterol Sulfate HfaAlbuterol Sulfate85$3,432
Ventolin HfaAlbuterol Sulfate29$1,812
Doxepin Hcl20$456
Ipratropium Bromide20$377
Prednisone51$337
Modafinil12$313
Azelastine Hcl17$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$36$281,38032 claims
GSKTrelegy Ellipta, Breo Ellipta$57$102,254129 claims
AstraZenecaBreztri Aerosphere$40$11,48815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 154 pulmonary disease providers in Oregon.

Other pulmonary disease in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →